[
1. Kunecki M, Oleksy T, Biernat J, Kukla P, Szwajkos K, Podolec P, Deja M, Gołba K, Płazak W. Ischemic conditioning of human heart muscle depends on opioid-receptor system. Folia Med Cracov. 2017;57(2):31-39.10.20418/jrcd.vol2no6.228
]Search in Google Scholar
[
2. Li PC, Yang YC, Hwang GY, Kao LS, Lin CY. Inhibition of reverse-mode sodium-calcium exchanger activity and apoptosis by levosimendan in human cardiomyocyte progenitor cell-derived cardiomyocytes after anoxia and reoxygenation. PLoS One. 2014;9(2):e85909.10.1371/journal.pone.0085909391190024498266
]Search in Google Scholar
[
3. Sorsa T, Polleselo P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitizer with cardiac troponin c. Moll Cell Biochem. 2004;266:87-107.10.1023/B:MCBI.0000049141.37823.1915646030
]Search in Google Scholar
[
4. Haikala H, Polleselo P. Calcium sensitivity enhancers. IDrugs. 2000;3:1199-205.
]Search in Google Scholar
[
5. Kaheinen P, Polleselo P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001;37:367-74.10.1097/00005344-200104000-0000311300649
]Search in Google Scholar
[
6. Erdei N, Papp Z, Polleselo P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol. 2006;148:696-702.10.1038/sj.bjp.0706781175187216715115
]Search in Google Scholar
[
7. Pollesello P, Papp Z. The cardioprotective effect of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007;50:257-63.10.1097/FJC.0b013e318098623017878752
]Search in Google Scholar
[
8. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Ilida H, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68:522-31.10.1067/mcp.2000.11097211103755
]Search in Google Scholar
[
9. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Verkkala K, et al. Effect of new calcium sensitizer levosimendan on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery by-pass grafting. Eur Heart J. 1998;19:660-8.10.1053/euhj.1997.08069597417
]Search in Google Scholar
[
10. Toller W, Algottson L, Guarracino F, Hormann C, Knotzer J, Lehman A, et al. Perioperative use of levosimendan: best practice in operative settings. J Cardiothorac Vasc Anesth. 2013;27:361-6.10.1053/j.jvca.2012.04.00722658687
]Search in Google Scholar
[
11. Rump AF, Acar D, Rosen R, Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol. 1994;74:2448.10.1111/j.1600-0773.1994.tb01106.x8090694
]Search in Google Scholar
[
12. Maytin M, Colucci WS. Cardioprotection: A new paradigm in the management of acute heart failure syndromes. Am J Cardiol. 2005;96:26G-31G.10.1016/j.amjcard.2005.07.01816181820
]Search in Google Scholar
[
13. Li PC, Yang YC, Hwang GY, Kao LS, Lin CY Inhibition of reverse-mode sodium-calcium exchanger activity and apoptosis by levosimendan in human cardiomyocyte progenitor cell-derived cardiomyocytes after anoxia and reoxygenation. PLoS One. 2014;9(2):e85909. 14. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol. 2004;68(5):807-12.10.1016/j.bcp.2004.05.01815294443
]Search in Google Scholar
[
14. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol. 2004;68(5):807-12.10.1016/j.bcp.2004.05.018
]Search in Google Scholar
[
15. Kunecki M, Płazak W, Roleder T, Biernat J, Oleksy T, Podolec P, Gołba KS. Opioidergic postconditioning’ of heart muscle during ischemia/reperfusion injury. Cardiol J. 2017;24(4):419-26.10.5603/CJ.a2016.009027734456
]Search in Google Scholar
[
16. Toller W, Heringlake M, Guarracino F, Algotson L, Alvarez J, Argyriadau H, et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol. 2015;184:323-36.10.1016/j.ijcard.2015.02.02225734940
]Search in Google Scholar
[
17. du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A. A role for the RISK pathway and KATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea-pig heart. Br J Pharmacol. 2008;154:41-50.10.1038/bjp.2008.52243898718297097
]Search in Google Scholar
[
18. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43:2177-82.10.1016/j.jacc.2004.02.05215193677
]Search in Google Scholar
[
19. Levijoki J, Pollesello P, Kaheinen P, Haikala H. Improved survival with simendan after experimental myocardial infarction in rats. Eur J Pharmacol. 2001;419:243-8.10.1016/S0014-2999(01)00997-911426847
]Search in Google Scholar
[
20. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17:125-30.
]Search in Google Scholar
[
21. Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol AL, et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome. Rev Esp Cardiol. 2008;61:471-9.10.1157/13119990
]Search in Google Scholar
[
22. Adegboyega PA, Haque AK, Boor PJ. Extensive myocytolysis as a marker of sudden cardiac death. Cardiovasc Pathol. 1996;5(6):315-21.10.1016/S1054-8807(96)00041-525851788
]Search in Google Scholar
, 